These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

519 related articles for article (PubMed ID: 21068523)

  • 1. Choosing the right heparin prophylaxis strategy in medical patients at risk for developing VTE: an evidence-based approach.
    Harrington DW
    Hosp Pract (1995); 2010 Nov; 38(4):18-28. PubMed ID: 21068523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meta-analysis of venous thromboembolism prophylaxis in medically Ill patients.
    Kanaan AO; Silva MA; Donovan JL; Roy T; Al-Homsi AS
    Clin Ther; 2007 Nov; 29(11):2395-405. PubMed ID: 18158080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of venous thromboembolism in hospitalized medical patients.
    Lenchus JD; Jaffer AK
    Mt Sinai J Med; 2008 Oct; 75(5):449-53. PubMed ID: 18828167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Geerts WH; Pineo GF; Heit JA; Bergqvist D; Lassen MR; Colwell CW; Ray JG
    Chest; 2004 Sep; 126(3 Suppl):338S-400S. PubMed ID: 15383478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An open-label comparison of the efficacy and safety of certoparin versus unfractionated heparin for the prevention of thromboembolic complications in acutely ill medical patients: CERTAIN.
    Schellong SM; Haas S; Greinacher A; Schwanebeck U; Sieder C; Abletshauser C; Bramlage P; Riess H
    Expert Opin Pharmacother; 2010 Dec; 11(18):2953-61. PubMed ID: 20950224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. VTE prophylaxis for the medical patient: where do we stand? - a focus on cancer patients.
    Cohen AT; Nandini B; Wills JO; Ota S
    Thromb Res; 2010 Apr; 125 Suppl 2():S21-9. PubMed ID: 20434000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The new oral anticoagulants, do they change the benefit vs. risk for thromboprophylaxis in association to ambulatory surgery?
    Squizzato A; Romualdi E; Dentali F; Ageno W
    Curr Opin Anaesthesiol; 2010 Dec; 23(6):722-5. PubMed ID: 20847691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Venous thromboembolism in the medically ill patient: a call to action.
    Bergmann JF; Kher A
    Int J Clin Pract; 2005 May; 59(5):555-61. PubMed ID: 15857352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thromboprophylaxis in surgical and medical patients.
    Bozzato S; Galli L; Ageno W
    Semin Respir Crit Care Med; 2012 Apr; 33(2):163-75. PubMed ID: 22648489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A retrospective review of the use of thromboprophylaxis in patients who subsequently developed a venous thromboembolism after discharge from hospital.
    Wiseman DN; Harrison J
    N Z Med J; 2010 Feb; 123(1309):37-49. PubMed ID: 20186241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective evaluation of venous thromboembolism prophylaxis in the adult cancer population.
    Reeves D; Liu CY
    J Oncol Pharm Pract; 2010 Mar; 16(1):27-31. PubMed ID: 19401307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of unfractionated heparin versus low-molecular-weight heparin and fondaparinux for pharmacologic venous thromboembolic prophylaxis in critically ill patients with cancer.
    Van Matre ET; Reynolds PM; MacLaren R; Mueller SW; Wright GC; Moss M; Burnham EL; Ho PM; Vandivier RW; Kiser TH
    J Thromb Haemost; 2018 Dec; 16(12):2492-2500. PubMed ID: 30347498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of new anticoagulants for the prevention of venous thromboembolism after major orthopaedic surgery and in hospitalised acutely ill medical patients.
    Ageno W; Spyropoulos AC; Turpie AG
    Thromb Haemost; 2012 Jun; 107(6):1027-34. PubMed ID: 22437976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unfractionated heparin versus low-molecular-weight heparin for venous thromboembolism prophylaxis in trauma.
    Jacobs BN; Cain-Nielsen AH; Jakubus JL; Mikhail JN; Fath JJ; Regenbogen SE; Hemmila MR
    J Trauma Acute Care Surg; 2017 Jul; 83(1):151-158. PubMed ID: 28426561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of venous thromboembolism in hospitalized acutely ill medical patients: focus on the clinical utility of (low-dose) fondaparinux.
    Di Nisio M; Porreca E
    Drug Des Devel Ther; 2013; 7():973-80. PubMed ID: 24068866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative effectiveness of low-molecular-weight heparin versus unfractionated heparin for thromboembolism prophylaxis for medical patients.
    Rothberg MB; Pekow PS; Lahti M; Lindenauer PK
    J Hosp Med; 2012; 7(6):457-63. PubMed ID: 22473716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticoagulation therapy for prevention and treatment of venous thromboembolic events in cancer patients: a review of current guidelines.
    Petersen LJ
    Cancer Treat Rev; 2009 Dec; 35(8):754-64. PubMed ID: 19762155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preventing venous thromboembolism in hospitalized patients with cancer: improving compliance with clinical practice guidelines.
    Brown A
    Am J Health Syst Pharm; 2012 Mar; 69(6):469-81. PubMed ID: 22382477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Venous thromboembolism in cancer patients.
    Deng A; Galanis T; Graham MG
    Hosp Pract (1995); 2014 Dec; 42(5):24-33. PubMed ID: 25485915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
    Kakkar VV; Howes J; Sharma V; Kadziola Z
    Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.